Awakn files a patent application in support of a new class of molecules for the treatment of addiction.
INVESTOR PROFILE | Ionic Brands
Company:
Ionic Brands
Symbol:
CSE: IONC
Country:
United States
Sector:
Legal Recreational Marijuana
Industry:
Concentrates and Vapes
Established:
2015
Website:
Company:
Ionic Brands
Symbol:
CSE: IONC
Country:
United States
Sector:
Legal Recreational Marijuana
Industry:
Concentrates and Vapes
Established:
2015
Website:
52-Week
Range N/A
Range N/A
Current
Outstanding 108,436,715
Outstanding 108,436,715
Warrants
Options
Fully Diluted
Market Cap.
14,639,000
14,639,000
IONIC BRANDS (CSE: IONC) has a premium portfolio of cannabis concentrate consumer brands. Ionic Brands is one of the top selling concentrate company in Washington State.
Company Brief
Ionic Brands (CSE: IONC) is creating a multi-state, consumer focused, premium cannabis porfolio consisting of iconic national brands.
They have:
- Stylish products
- World Class Management Team
- A proven and repeatable strategy for success
Highlights
Experienced and proven luxury cannabis concentrates brand
One of the tops selling vape brands in WA State with a loyal customer base
Largest standalone oil manufacturer in the state of WA
Consistent sales growth over 3 years with a verified marketing blueprint
Offers investors exposure to a premium luxury cannabis brand
Demonstrated to have a winning formula to become the top vape company in WA
Massive growth opportunity available with expansion into OR, NV and CA
In The News
Ionic Is Changing the Face of Cannabis and Creating a Social Revolution
It’s all in the URL: Ionic.social. “We believe our products are best when enjoyed in a social setting,” said co-founder Christian Struzan.
READ MORE
Marijuana Vaping Is The Most Explosive Growth Play In Marijuana Today
“Nobody smokes marijuana anymore, they vape it.” - New York Times That's not quite true. But it will be soon.
READ MORE
How To Invest In Marijuana Vaping
The marijuana vaporization products (or just "vape") market is set to explode in 2019.
READ MORE
Related Articles
MINDCURE Announces Financial Results for the Second Quarter of Fiscal 2022
MINDCURE reports its Q2 fiscal 2022 results. The Company recorded a loss of CAD$2.95 million. Its cash position is now CAD$13.4 million.
FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder
Mindmed receives IND clearance from the FDA for MM-120, paving the way for its Phase IIb clinical trial for generalized anxiety disorder.
Mydecine Partners with Combat Stress to Treat Post-Traumatic Stress Disorder in Veterans
Mydecine announces a partnership with Combat Stress and King's College London to provide psychoactive-assisted therapy for PTSD.
Novamind Announces CAD$5 Million Private Placement with Institutional Investor
Novamind announces a CAD$5 million placement with a single institutional investor. Units are priced at CAD$0.40 with a full warrant at CAD$0.50.
Numinus Wellness Inc. Reports Q1 2022 Results
Numinus Wellness reports Q1 2022 results, including quarterly revenues of CAD$0.8 million and a gross profit of CAD$50,965.